MCMedicalCodingSoftware
Q0144

Q0144: Azithromycin dihydrate, oral, capsules/powder, 1 gram

HCPCSActiveBETOS O1E

Q0144 is a HCPCS Level II code for azithromycin dihydrate, oral, capsules/powder, 1 gram. It belongs to the Temporary Codes section. Medicare does not pay it: see the coverage note below before you bill it.

Medicare coverage: Non-covered by Medicare

Medicare does not cover the item or service this code describes.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.

Physician fee schedule statusN

Non-covered service. Medicare does not cover it.

Global period: XXX

Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.

Medically Unlikely Edits: units per day

The most units of Q0144 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.

practitioner
0, never payable
MAI 3: Date of Service Edit: Clinical · CMS Policy
outpatient
0, never payable
MAI 3: Date of Service Edit: Clinical · CMS Policy
DME supplier
0, never payable
MAI 3: Date of Service Edit: Clinical · CMS Policy

The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.

The CMS record for Q0144

Long descriptor
Azithromycin dihydrate, oral, capsules/powder, 1 gram

The official wording. This is what the code means.

Short descriptor
Azithromycin dihydrate, oral

CMS's 28-character form, which is what shows up on a remittance advice.

Added
July 1, 1996

When CMS introduced the code.

BETOS
O1E

Berenson-Eggers Type of Service: CMS's own analytic grouping.

Pricing indicator
00: Not priced by Part B

Service not separately priced by Part B, not covered, bundled into another service, or used by Part A only.

Codes adjacent to Q0144

HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If Q0144 is not quite right, the correct code is very often within a few positions of it.

  • Q0092Set-up portable x-ray equipment
  • Q0111Wet mounts, including preparations of vaginal, cervical or skin specimens
  • Q0112All potassium hydroxide (koh) preparations
  • Q0113Pinworm examinations
  • Q0114Fern test
  • Q0115Post-coital direct, qualitative examinations of vaginal or cervical mucous
  • Q0138Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
  • Q0139Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
  • Q0155Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0161Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0162Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0163Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen
  • Q0164Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0166Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
  • Q0167Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0169Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
HCPCS Level II2026Q4-Oct· effective October 1, 2026